A simple method to estimate survival trajectories Dr. Matt Williams ICHNT & IC E-Oncology Feb 2015

Slides:



Advertisements
Similar presentations
METHODOLOGY FOR META- ANALYSIS OF TIME TO EVENT TYPE OUTCOMES TO INFORM ECONOMIC EVALUATIONS Nicola Cooper, Alex Sutton, Keith Abrams Department of Health.
Advertisements

Treatment in Advanced Non-Small Cell Lung Cancer.
Health Literacy: how to explain risk? Dr. Keiko Yasukawa University of Technology, Sydney.
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
Survivorship Update February 2012
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
Casulo C et al. Proc ASH 2013;Abstract 510.
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Survivorship – why bother? Jane Maher NHS Improvement Lead (cancer) Chief Medical Officer, Macmillan cancer Support Chair NCSI Consequences of treatment.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Correcting for measurement error in nutritional epidemiology Ruth Keogh MRC Biostatistics Unit MRC Centre for Nutritional Epidemiology in Cancer Prevention.
Point Estimation: Odds Ratios, Hazard Ratios, Risk Differences, Precision Elizabeth S. Garrett Oncology Biostatistics March 20, 2002 Clinical.
EVIDENCE BASED MEDICINE
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Ethical issues and cancer screening. Efficacy The extent to which a specific intervention, procedure, regimen, or service produces a beneficial result.
Dr. Rico Liu Consultant, Department of Clinical Oncology, Queen Mary Hospital Honorary Clinical Associate Professor, Department of Clinical Oncology, The.
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Cancer associated chronic illness - a new cancer story Jane Maher NHS Improvement Lead (cancer) CMO Macmillan cancer Support Chair NCSI Consequences of.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Phase III studies of Xeloda® in colorectal cancer (CRC)
Cancer and How to avoid it QUB Staff wellbeing Initiative Dr Anna Gavin Director, N. Ireland Cancer Registry Queen’s University Belfast 29 th January2014.
What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.
Il punto di vista del clinico Fabio Puglisi, MD PhD Ruolo della terapia antiangiogenica nel carcinoma mammario.
NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Effect of Early Palliative Care (PC) on Quality of Life (QOL), Aggressive Care at the End-of- Life (EOL), and Survival in Stage IV NSCLC Patients: Results.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Modeling Cure Rates Using the Survival Distribution of the General Population Wei Hou 1, Keith Muller 1, Michael Milano 2, Paul Okunieff 1, Myron Chang.
The more it hurts, the better it works?
Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
1 News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin) Paul Donnellan Consultant Medical Oncologist Galway University Hospitals.
Patricia Guyot1,2, Nicky J Welton1, AE Ades1
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Dr Heather O Dickinson Department of Child Health University of Newcastle
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
GBM – Oncological Management Dr H Lord Consultant Clinical Oncologist.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Prognosis study EBM questions. Prognostic factors Characteristics of patient that may predict eventual outcome Several types: demographic (eg age) disease-specific.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
Incidence and prognosis of hepatocellular adenoma in Denmark Lars Bossen Departments of Hepatology and Gastroenterology and Clinical Epidemiology Aarhus.
Pancreatic Cancer in the US – 12/2015 TIMOTHY PAULUS - TESTIMONY 1/20/2016.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
National Cancer Survivorship Initiative Ciarán Devane Chief Executive, Macmillan Cancer Support.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
For more information please visit
Brain imaging prior to lung cancer resection
Cancer – advances in treatment and The impact on underwriting and claims Dr. Andreas Armuss.
What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,
Volume 148, Issue 1, Pages (January 2012)
Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer  Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,
Role for XRT in treatment of early stage Follicular lymphoma?
CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)
Presentation transcript:

A simple method to estimate survival trajectories Dr. Matt Williams ICHNT & IC E-Oncology Feb 2015

The need people diagnosed a year with cancer (UK, 2011) cancer deaths (UK, 2012) Lung, bowel, breast, prostate – 54% cases, 46% of deaths May be diagnosed with incurable disease (e.g. Lung) May initially be treated curatively, and then relapse (e.g Breast) Once diagnosed with “incurable” disease, may still be treated and live for many years CRUK Cancer Stats (2015)

Talking about survival Curable/ incurable “In the long run, we are all dead” Prognostic factors Bias survival one way or another Patient & Tumour factors (age, fitness; tumour grade, molecular aspects) Clinicians are bad at predicting prognosis Survival remains a process, of a population, over time JM Keynes, 1923

Looking at survival Williams et al., Clin Onc, 2013

How can we characterise survival? Stockler et al., BJC, 2006

If it is exponential Constant risk E.g. radioactive decay Multiples of the median estimate other points 75% ~ median/2 25% ~ median x 2 Assumes no cure No conditional survival

Metastatic Colorectal cancer Trials of patients receiving first-line palliative chemotherapy 2000 – 2011, phase III, 2+ regimens, 100+ pts per arm, 75% of pts had died 46 trials 96 curves for analysis 96 points at 90%, 75%, 25%; 54 points at 10% Obtained median survival Median/4; median/2; median * 2; median *3 Agreement defined calculated being 0.75 – 1.33 actual figure

Metastatic Colorectal cancer 46 trials; patients Median OS 16.8 (IQR: 14.3 – 19.4) 342 data points 301 (88%) acceptable Worst agreement at 90% level (76% agreement) Tendency to underestimate time to 90% and 75%, over-estimate to 25% and 10% Williams et al., Ann Onc, 2014

Related work Breast, Lung and Prostate cancer We now have data on cancer accounting for ~ half all cancer deaths GBM in progress Clinicians aren’t accurate, but are good enough at estimating the median survival We are discussing collaboration with Sydney group Kiely et al., JCO 2013 Kiely et al., JCO, 2011 Kiely et al., Lung Cancer, 2012 West et al., EJC, 2014

Computational aspects Very simple computation ! (1/4, ½, *2, *3) Based on a mathematical understanding of an empirical observation Widely applicable Helps us think about clinical practice Orthogonal to other prognostic tools Better prognostic estimates improve estimates of the median

Thanks Anna Lerner & Ramsay Singer Martin Utley (UCL) for discussion ICHNT & ICRUK centre supporting my work